GSK 
Welcome,         Profile    Billing    Logout  
 323 Products   957 Diseases   323 Products   1268 Trials   64372 News 


«12...678910111213141516...750751»
  • ||||||||||  Enrollment open:  Migraine Medication Effects on Urinary Symptoms (clinicaltrials.gov) -  Mar 29, 2024   
    P=N/A,  N=200, Enrolling by invitation, 
    Not yet recruiting --> Enrolling by invitation
  • ||||||||||  Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
    Enrollment closed, Trial primary completion date, MRI:  ETHA: Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma (clinicaltrials.gov) -  Mar 29, 2024   
    P3,  N=31, Active, not recruiting, 
    Not yet recruiting --> Enrolling by invitation Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2024 --> Aug 2023
  • ||||||||||  belrestotug (EOS-448) / iTeos, GSK
    Enrollment change, Trial completion date, Trial termination, Combination therapy:  Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) -  Mar 28, 2024   
    P1/2,  N=16, Terminated, 
    N=162 --> 16 | Trial completion date: Dec 2025 --> Nov 2023 | Recruiting --> Terminated; Company operational decision. Decision to stop study is not due to safety or efficacy concerns
  • ||||||||||  Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
    Journal:  Botulinum toxin: a new differential diagnosis for a lytic bone lesion. (Pubmed Central) -  Mar 28, 2024   
    Our search of the literature failed to identify any previous cases of this occurring. However, as the popularity of this cosmetic procedure only increases, we believe that this represents an important possible differential for isolated lytic lesion after administration of "Botox" injection.
  • ||||||||||  IMCnyeso / GSK, Miostat (carbachol) / Novartis, GSK4524101 / GSK
    Journal:  TRPV4 Activation during Guinea Pig Airway Smooth Muscle Contraction Promotes Ca2+ and Na+ Influx. (Pubmed Central) -  Mar 28, 2024   
    In single myocytes, the TRPV4 agonist (GSK101) evoked an increase in [Ca2+]i, characterized by a slow onset and a plateau phase...We conclude that contraction of ASM cells after stimulation with His or CCh promotes TRPV4 activation, the subsequent influx of Ca2+ and Na+, and the opening of L-VDCCs. The entry of Ca2+ into ASM cells via TRPV4 and L-VDCCs contributes to optimal smooth muscle contraction.
  • ||||||||||  I-BET151 / GSK
    Journal:  Chromatin Remodeling-Related PRDM1 Increases Stomach Cancer Proliferation and Is Counteracted by Bromodomain Inhibitor. (Pubmed Central) -  Mar 28, 2024   
    Through applying systematic bioinformatic analysis, we determined that out of 31 chromatin remodeling factors in six gastrointestinal cancers, only PR/SET domain 1 (PRDM1) showed both expression alteration and prognosis prediction. Analyses on pathways, therapies, and mediators showed that cell cycle, bromodomain inhibitor IBET151, and BET protein BRD4 were, respectively involved in PRDM1-high stomach cancer, while cell line experiments validated that PRDM1 knockdown in human stomach cancer cell line SNU-1 decreased its proliferation, BRD4 expression, and responsiveness to IBET151; accordingly, these results indicate the contribution by PRDM1 in stomach cancer formation and its association with BRD4 modulation as well as BET inhibitor treatment.
  • ||||||||||  Xenical (orlistat) / Roche, GSK, chlorogenic acid / Jiuzhang Biotech
    Journal:  Exploring Beneficial Properties of Haskap Berry Leaf Compounds for Gut Health Enhancement. (Pubmed Central) -  Mar 28, 2024   
    The analysis of antioxidant capacity, assessed through ABTS, CUPRAC, DPPH, and FRAP assays, revealed varying but consistently high levels across extracts, with Extract 3 (loganic acid: 2.974 mg/g, chlorogenic acid: 1.125 mg/g, caffeic acid: 0.083 mg/g, rutin: 1.137 mg/g, and quercetin: 1.501 mg/g) exhibiting the highest values (ABTS: 0.2447 mg/mL, CUPRAC: 0.3121 mg/mL, DPPH: 0.21001 mg/mL, and FRAP: 0.3411 mg/mL). Subsequent enzymatic inhibition assays demonstrated a notable inhibitory potential against ?-glucosidase (1.4915 mg/mL, expressed as acarbose equivalent), hyaluronidase (0.2982 mg/mL, expressed as quercetin equivalent), and lipase (5.8715
  • ||||||||||  Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
    Review, Journal:  Esophagogastric Junction Outflow Obstruction (EGJOO): A Manometric Phenomenon or Clinically Impactful Problem. (Pubmed Central) -  Mar 28, 2024   
    Uncontrolled trials show effectiveness for pneumatic dilation and peroral endoscopic myotomy to treat confirmed EGJOO; Botox and Heller myotomy may also be considered but data for confirmed EGJOO is more limited...PD and POEM are effective in confirmed EGJOO, Heller myotomy may also be considered but data for confirmed EGJOO is limited. Randomized controlled trials are needed to clarify optimal management of EGJOO.
  • ||||||||||  Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
    Journal:  Partial facial paralysis induced by sialolithiasis of the parotid gland: a case report. (Pubmed Central) -  Mar 27, 2024   
    It underscores the potential involvement of parotid sialolithiasis, particularly in patients with a history of recurrent parotitis or facial trauma. Prompt recognition of such uncommon presentations can prevent undue interventions, aid in timely appropriate management, and significantly contribute to the patient's recovery and prevention of long-term complications.
  • ||||||||||  Nimenrix (MenACWY-TT) / Pfizer, Bexsero (meningococcal group B vaccine) / GSK
    Journal:  Immunogenicity and Protective Capacity of CpG ODN Adjuvanted Alum Adsorbed Bivalent Meningococcal Outer Membrane Vesicle Vaccine. (Pubmed Central) -  Mar 27, 2024   
    We present such a case in a nine-year-old female patient with a vertebral aneurysmal bone cyst, who received dental extractions subsequent to denosumab therapy. BALB/c mice were immunized with preclinical batches of the W+B OMV vaccine, either adjuvanted with Alum, CpG ODN or their combinations and compared with a MenACYW conjugate vaccine (NimenrixTM, Pfizer) and a MenB OMV-based vaccine (Bexsero
  • ||||||||||  Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
    Journal:  Botox Optimization Algorithm: A New Human-Based Metaheuristic Algorithm for Solving Optimization Problems. (Pubmed Central) -  Mar 27, 2024   
    Comparative analysis against twelve well-known metaheuristic algorithms demonstrates the BOA's superior performance across various benchmark functions, with statistically significant advantages. Moreover, application to constrained optimization problems from the CEC 2011 test suite highlights the BOA's effectiveness in real-world optimization tasks.
  • ||||||||||  Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
    Retrospective data, Journal:  OnabotulinumtoxinA as a promising treatment for primary trochlear headache: A retrospective case series. (Pubmed Central) -  Mar 27, 2024   
    From a clinical standpoint, having a safer alternative is of paramount significance for patients with limited treatment options, such as those with PRTH. Further research is warranted to validate these findings and explore the long-term efficacy of BoNTA in PRTH management.
  • ||||||||||  KYN-5356 / Kynexis, GSK256073 / GSK, SCH 900271 / Merck (MSD)
    Journal:  Anthranilic Acid, a GPR109A Agonist, and Schizophrenia. (Pubmed Central) -  Mar 27, 2024   
    Future research might explore antipsychotic effects of (1) human pegylated kynureninase, an enzyme that catalyzes formation of AA from kynurenine (Kyn); (2) inhibitors of Kyn conversion into kynurenic acid, for example, KYN5356, to patients with already impaired Kyn conversion into 3-hydroxykynurenine; (3) synthetic GPR 109A agonists, for example, MK-1903 and SCH900271 and GSK256073, that underwent clinical trials as anti-dyslipidemia agents. GPR109A expression, that might be a new endophenotype of schizophrenia, especially associated with cognitive impairment, needs thorough assessment.
  • ||||||||||  Ojjaara (momelotinib) / GSK
    Journal:  Momelotinib bei Myelofibrose und An (Pubmed Central) -  Mar 27, 2024   
    In a real-world clinical setting where there may be poor adherence to prescribed therapy, our findings suggest a significant therapeutic advantage for longer-acting ICS molecules in patients with asthma. No abstract available
  • ||||||||||  Dysport (abobotulinumtoxinA) / Ipsen, Xeomin (incobotulinumtoxinA) / Merz Pharma, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
    Journal:  Trends in Botulinum Toxin-Related Industry Payments to Physicians. (Pubmed Central) -  Mar 26, 2024   
    Growing amounts are being paid to physicians for BTX-related activities-both medical and aesthetic. Despite the variety of indications for BTX within otolaryngology, otolaryngology payments were overshadowed by other specialties, which may reflect greater BTX utilization in those specialties.
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  A narrative review of the pharmaceutical management of osteoporosis. (Pubmed Central) -  Mar 26, 2024   
    Hormonal therapies are used if patients cannot tolerate bisphosphonates or denosumab or are refractory to these medications. Preventative measures for osteoporosis include tailored exercise and sufficient intake of calcium and vitamin D via diet or supplementation.